Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Does the frequency of routine follow-up after curative treatment for head-and-neck cancer affect survival?

Hall SF, Owen T, Griffiths RJ, Brennan K.

Curr Oncol. 2019 Oct;26(5):295-306. doi: 10.3747/co.26.4949. Epub 2019 Oct 1.

2.

Explaining the Variation in Surgical Practice for Differentiated Thyroid Cancer in Ontario, Canada.

Hall SF, Irish JC, Griffiths RJ, Whitehead M.

JAMA Otolaryngol Head Neck Surg. 2019 Aug 29. doi: 10.1001/jamaoto.2019.2304. [Epub ahead of print]

PMID:
31465105
3.

The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting.

Hall SF, Griffiths RJ, O'Sullivan B, Liu FF.

Head Neck. 2019 Jul;41(7):2271-2276. doi: 10.1002/hed.25679. Epub 2019 Feb 4.

4.

Oxidative β-C-H sulfonylation of cyclic amines.

Griffiths RJ, Kong WC, Richards SA, Burley GA, Willis MC, Talbot EPA.

Chem Sci. 2018 Jan 22;9(8):2295-2300. doi: 10.1039/c7sc04900e. eCollection 2018 Feb 28.

5.

Variation in routine follow-up care after curative treatment for head-and-neck cancer: a population-based study in Ontario.

Brennan KE, Hall SF, Owen TE, Griffiths RJ, Peng Y.

Curr Oncol. 2018 Apr;25(2):e120-e131. doi: 10.3747/co.25.3892. Epub 2018 Apr 30.

6.

Evaluation of treatment outcomes in patients with supraglottic laryngeal cancer in Ontario, Canada: A population-based study.

Hall SF, Griffiths RJ.

Head Neck. 2018 May;40(5):1024-1033. doi: 10.1002/hed.25073. Epub 2018 Feb 7.

PMID:
29412495
7.

Transition-Metal-Free Amine Oxidation: A Chemoselective Strategy for the Late-Stage Formation of Lactams.

Griffiths RJ, Burley GA, Talbot EP.

Org Lett. 2017 Feb 17;19(4):870-873. doi: 10.1021/acs.orglett.7b00021. Epub 2017 Feb 8.

8.

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.

Freeman-Cook KD, Reiter LA, Noe MC, Antipas AS, Danley DE, Datta K, Downs JT, Eisenbeis S, Eskra JD, Garmene DJ, Greer EM, Griffiths RJ, Guzman R, Hardink JR, Janat F, Jones CS, Martinelli GJ, Mitchell PG, Laird ER, Liras JL, Lopresti-Morrow LL, Pandit J, Reilly UD, Robertson D, Vaughn-Bowser ML, Wolf-Gouviea LA, Yocum SA.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34. Epub 2007 Sep 29.

PMID:
17935984
9.

C1-esterase inhibitor deficiency and elective caesarean section.

Griffiths RJ, O'Sullivan G.

Int J Obstet Anesth. 2005 Jul;14(3):263-4.

PMID:
15935642
10.

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1807-10.

PMID:
15780611
11.

Silenes as novel synthetic reagents: identification of a practical method for silene generation and trapping.

Berry MB, Griffiths RJ, Sanganee MJ, Steel PG, Whelligan DK.

Org Biomol Chem. 2004 Aug 21;2(16):2381-92. Epub 2004 Jul 28.

PMID:
15305223
12.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95.

PMID:
15177439
13.

Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice.

Beierschmitt WP, McNeish JD, Griffiths RJ, Nagahisa A, Nakane M, Amacher DE.

Toxicol Sci. 2001 Sep;63(1):15-21.

PMID:
11509739
14.

Altered cytokine production in mice lacking P2X(7) receptors.

Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA.

J Biol Chem. 2001 Jan 5;276(1):125-32.

16.

Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.

Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, McNeish JD, Eastman SE, Howard ED, Clarke SR, Rosloniec EF, Elliott EA, Rudensky AY.

Immunity. 1999 Feb;10(2):207-17.

17.

The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.

Showell HJ, Conklyn MJ, Alpert R, Hingorani GP, Wright KF, Smith MA, Stam E, Salter ED, Scampoli DN, Meltzer S, Reiter LA, Koch K, Piscopio AD, Cortina SR, Lopez-Anaya A, Pettipher ER, Milici AJ, Griffiths RJ.

J Pharmacol Exp Ther. 1998 Jun;285(3):946-54.

PMID:
9618393
18.
19.
20.

Analgesic activity of 2-amino-4-methylpyridine, a novel NO synthase inhibitor.

Pettipher ER, Hibbs TA, Smith MA, Griffiths RJ.

Inflamm Res. 1997 Aug;46 Suppl 2:S135-6. No abstract available.

PMID:
9297548
21.

Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.

Carty TJ, Sweeney FJ, Griffiths RJ, Eskra JD, Ernest MJ, Pillar JS, Cheng JD, Loose LD, Joseph PA, Pazoles PP, Moore PF, Nagahisa A, Murase S, Kadin SB.

Inflamm Res. 1997 May;46(5):168-79.

PMID:
9197987
22.

Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice.

Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ, Scampoli DN, Eskra JD, Byrum RS, Koller BH, McNeish JD.

J Exp Med. 1997 Mar 17;185(6):1123-9.

23.

Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses.

Byrum RS, Goulet JL, Griffiths RJ, Koller BH.

J Exp Med. 1997 Mar 17;185(6):1065-75.

24.

The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.

Cheng JB, Watson JW, Pazoles CJ, Eskra JD, Griffiths RJ, Cohan VL, Turner CR, Showell HJ, Pettipher ER.

J Pharmacol Exp Ther. 1997 Feb;280(2):621-6.

PMID:
9023272
25.

Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.

Pettipher ER, Labasi JM, Salter ED, Stam EJ, Cheng JB, Griffiths RJ.

Br J Pharmacol. 1996 Apr;117(7):1530-4.

26.

GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF.

Brissette WH, Baker DA, Stam EJ, Umland JP, Griffiths RJ.

Cytokine. 1995 Apr;7(3):291-5.

PMID:
7640348
27.
28.

ATP induces the release of IL-1 from LPS-primed cells in vivo.

Griffiths RJ, Stam EJ, Downs JT, Otterness IG.

J Immunol. 1995 Mar 15;154(6):2821-8.

PMID:
7876552
29.

Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.

Griffiths RJ, Pettipher ER, Koch K, Farrell CA, Breslow R, Conklyn MJ, Smith MA, Hackman BC, Wimberly DJ, Milici AJ, et al.

Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):517-21.

30.

(+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.

Koch K, Melvin LS Jr, Reiter LA, Biggers MS, Showell HJ, Griffiths RJ, Pettipher ER, Cheng JB, Milici AJ, Breslow R, et al.

J Med Chem. 1994 Sep 30;37(20):3197-9. No abstract available.

PMID:
7932545
31.

Breast pads: their effectiveness and use by lactating women.

Griffiths RJ.

J Hum Lact. 1993 Mar;9(1):19-26.

PMID:
8489718
34.

The effect of FK506 and cyclosporin A on antigen-induced arthritis.

Blackham A, Griffiths RJ.

Clin Exp Immunol. 1991 Nov;86(2):224-8.

36.

FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor.

Blackham A, Griffiths RJ, Hallam C, Mann J, Mitchell PD, Norris AA, Simpson WT.

Agents Actions. 1990 Jun;30(3-4):432-42.

PMID:
2117338
37.

Effects of ciclosporin and protein synthesis inhibitors on cutaneous inflammation in mouse skin.

Griffiths RJ, Wood BE, Li S, Blackham A.

Skin Pharmacol. 1989;2(1):30-7.

PMID:
2560651
38.
39.

A modified mouse air pouch model for evaluating the effects of compounds on granuloma induced cartilage degradation.

Bottomley KM, Griffiths RJ, Rising TJ, Steward A.

Br J Pharmacol. 1988 Mar;93(3):627-35.

40.

Lactation management--the doctor's role.

Griffiths RJ, Thornton LR.

S Afr Med J. 1987 Nov 7;72(9):590-1. No abstract available.

PMID:
3686291
41.

36-MeV-triton-induced charge exchange: Mass measurements and energy levels of neutron-rich nuclei and the charge exchange reaction mechanism.

Pearce KI, Clarke NM, Griffiths RJ, Simmonds PJ, Dodd aA, Barker D, England JB, Mannion MC, Ogilvie CA.

Phys Rev C Nucl Phys. 1987 May;35(5):1617-1630. No abstract available.

PMID:
9953949
42.

Haemoglobin A1c levels in normal and diabetic pregnancies.

Griffiths RJ, Vinall PS, Stickland MH, Wales JK.

Eur J Obstet Gynecol Reprod Biol. 1987 Mar;24(3):195-200.

PMID:
3556725
43.

Pulmonary tuberculosis due to Mycobacterium bovis.

Wilkins EG, Griffiths RJ, Roberts C.

Thorax. 1986 Sep;41(9):685-7.

44.

Tuberculous meningitis due to Mycobacterium bovis: a report of two cases.

Wilkins EG, Griffiths RJ, Roberts C, Green HT.

Postgrad Med J. 1986 Jul;62(729):653-5.

45.
46.

Bovine tuberculosis of the skin.

Wilkins EG, Griffiths RJ, Roberts C.

J Infect. 1986 May;12(3):280-1. No abstract available.

PMID:
3522752
47.

Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung.

Berry CN, Griffiths RJ, Hoult JR, Moore PK, Taylor GW.

Br J Pharmacol. 1986 Feb;87(2):327-35.

48.

Nuclear shell effects in helion polarization phenomena.

Hanspal JS, Griffiths RJ, Clarke NM.

Phys Rev C Nucl Phys. 1985 Apr;31(4):1138-1146. No abstract available.

PMID:
9952636
49.

The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.

Wilsoncroft PS, Lofts FJ, Griffiths RJ, Moore PK.

J Pharm Pharmacol. 1985 Feb;37(2):139-41.

PMID:
2858551
50.

Age-dependent changes in the synthesis and catabolism of 6 oxo PGE1 and other prostanoids by the rat kidney in vitro.

Griffiths RJ, Berry CN, Hoult JR, Moore PK.

Biochem Pharmacol. 1985 Jan 15;34(2):223-8.

PMID:
3881101

Supplemental Content

Loading ...
Support Center